Loading company
$2.81-3.3%Nov 9 close
Next earnings: December 3, 2026
Figures through December 31, 2025, from the 20-F filed May 15, 2026
Past performance
- 1W
- -3.3%
- 1M
- -6.8%
- 3M
- -52.9%
- 6M
- -59.2%
- 1Y
- -67.4%
- 5Y
- -98.3%
Built from Addex Therapeutics Ltd.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This company files in CHF. Figures are converted to US dollars at $1.00 = 0.833140 CHF, the current rate, applied to every period alike — so growth and margins are the company’s own and not the exchange rate’s. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
$2.81-3.3%Nov 9 close
Next earnings: December 3, 2026
Figures through December 31, 2025, from the 20-F filed May 15, 2026
The themes Addex Therapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.$48BA+
EXELExelixis, Inc.$17.3BA+
JAZZJazz Pharmaceuticals plc$15.9BA
HALOHalozyme Therapeutics, Inc.$11.6BA+
TECHBIO-Techne Corp$11.4BA+Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
BIIBBiogen Inc.Oct 28, 2026BAGraded B, now AGrade D-
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 25 quarters of Addex Therapeutics Ltd.’s grade history. The other 23 go back to April 2020.